Qiagen (NYSE:QGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Qiagen (NYSE:QGEN) has received an average rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $50.07.

Several analysts recently weighed in on QGEN shares. Jefferies Financial Group restated a “buy” rating and issued a $52.50 price objective (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Morgan Stanley restated an “equal weight” rating and issued a $46.67 price objective (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective for the company. in a report on Thursday, October 17th. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a research note on Thursday, October 17th.

Hedge Funds Weigh In On Qiagen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its stake in shares of Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after acquiring an additional 500 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of Qiagen by 41.5% during the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock worth $38,000 after purchasing an additional 251 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Qiagen during the third quarter worth about $53,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Qiagen by 83.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company’s stock worth $70,000 after purchasing an additional 712 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

QGEN stock opened at $44.66 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The business has a 50-day moving average price of $43.72 and a 200 day moving average price of $43.21. The company has a market capitalization of $9.91 billion, a P/E ratio of 111.32, a PEG ratio of 3.03 and a beta of 0.37. Qiagen has a 1-year low of $40.15 and a 1-year high of $49.30.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.